Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences

被引:36
|
作者
Del Prete, Gregory Q. [1 ]
Lifson, Jeffrey D. [1 ]
Keele, Brandon F. [1 ]
机构
[1] Frederick Natl Lab Canc Res, AIDS & Canc Virus Program, Leidos Biomed Res Inc, Frederick, MD USA
基金
美国国家卫生研究院;
关键词
macaque; simian-human immunodeficiency virus; simian immunodeficiency virus; vaccine challenge; SIMIAN IMMUNODEFICIENCY VIRUS; RHESUS MACAQUES; MENSTRUAL-CYCLE; NEUTRALIZATION SENSITIVITY; DISEASE PROGRESSION; CYNOMOLGUS MACAQUES; PARTIAL PROTECTION; SIV CHALLENGES; INFECTION; SHIV;
D O I
10.1097/COH.0000000000000311
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewNonhuman primate (NHP) models of AIDS are powerful systems for evaluating HIV vaccine approaches in vivo. Authentic features of HIV-1 transmission, dissemination, target cell tropism, and pathogenesis, and aspects of anti-HIV-1 immune responses, can be recapitulated in NHPs provided the appropriate, specific model parameters are considered. Here, we discuss key model parameter options and their implications for HIV-1 vaccine evaluation.Recent findingsWith the availability of several different NHP host species/subspecies, different challenge viruses and challenge stock production methods, and various challenge routes and schemata, multiple NHP models of AIDS exist for HIV vaccine evaluation. The recent development of multiple new challenge viruses, including chimeric simian-human immunodeficiency viruses and simian immunodeficiency virus clones, improved characterization of challenge stocks and production methods, and increased insight into specific challenge parameters have resulted in an increase in the number of available models and a better understanding of the implications of specific study design choices.SummaryRecent progress and technical developments promise new insights into basic disease mechanisms and improved models for better preclinical evaluation of interventions to prevent HIV transmission.
引用
收藏
页码:546 / 554
页数:9
相关论文
共 50 条
  • [41] HUMAN T-CELL EPITOPES ON HIV-1 - STRATEGIES FOR VACCINE DEVELOPMENT
    ENNIS, FA
    LITTAUA, RA
    TAKAHASHI, K
    WEST, K
    DAI, LC
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1993, 9 : S42 - S42
  • [42] NK Cells in HIV-1 Infection: From Basic Science to Vaccine Strategies
    Florez-Alvarez, Lizdany
    Hernandez, Juan C.
    Zapata, Wildeman
    FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [43] Immune Complex Vaccine Strategies to Combat HIV-1 and Other Infectious Diseases
    Tang, Alex F.
    Enyindah-Asonye, Gospel
    Hioe, Catarina E.
    VACCINES, 2021, 9 (02) : 1 - 21
  • [44] The evaluation of immunological safety of the CombiHIVvac candidate vaccine against HIV-1
    Gamaley, S. G.
    Sysoeva, G. M.
    Danilenko, E. D.
    Masycheva, V. I.
    Karpenko, L. I.
    CYTOKINE, 2009, 48 (1-2) : 73 - 73
  • [45] Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
    Letourneau, Sven
    Im, Eung-Jun
    Mashishi, Tumelo
    Brereton, Choechoe
    Bridgeman, Anne
    Yang, Hongbing
    Dorrell, Lucy
    Dong, Tao
    Korber, Bette
    McMichael, Andrew J.
    Hanke, Tomas
    PLOS ONE, 2007, 2 (10):
  • [46] Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine
    Sanders, Rogier W.
    EXPERT REVIEW OF VACCINES, 2011, 10 (08) : 1117 - 1120
  • [47] HIV-1 vaccine candidate evaluation in non-human primates
    Lu, YC
    CRITICAL REVIEWS IN ONCOGENESIS, 1997, 8 (2-3): : 273 - 291
  • [48] An Evaluation of Selected Populations for HIV-1 Vaccine Cohort Development in Nigeria
    Njoku, Ogbonnaya S.
    Manak, Mark M.
    O'Connell, Robert J.
    Shutt, Ashley L. W.
    Malia, Jennifer A.
    Heipertz, Richard A., Jr.
    Tovanabutra, Sodsai
    Milazzo, Mark J.
    Akintunde, Gideon Akindiran
    Alabi, Abraham S.
    Suleiman, Aminu
    Ogundeji, Amos A.
    Kene, Terfa S.
    Nelson, Robbie
    Ayemoba, Ojor R.
    Singer, Darrell E.
    Robb, Merlin L.
    Peel, Sheila A.
    Michael, Nelson L.
    PLOS ONE, 2016, 11 (12):
  • [49] HIV-1 diversity in Brazil:: Genetic, biologic, and immunologic characterization of HIV-1 strains in three potential HIV vaccine evaluation sites
    Bongertz, V
    Bou-Habib, DC
    Brígido, LFM
    Caseiro, M
    Chequer, PJN
    Couto-Fernandez, JC
    Ferreira, PC
    Galvao-Castro, B
    Greco, D
    Guimaraes, ML
    de Carvalho, MIL
    Morgado, MG
    Oliveira, CAF
    Osmanov, S
    Ramos, CA
    Rossini, M
    Sabino, E
    Tanuri, A
    Ueda, M
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (02) : 184 - 193
  • [50] STUDIES ON HIV-1 VACCINES BY THE AIDS VACCINE EVALUATION GROUP (AVEG)
    BELSHE, RB
    BOLOGNESI, D
    CLEMENTS, ML
    COREY, L
    FAST, P
    GRAHAM, B
    KEEFER, M
    MESTECKY, J
    MULLIGAN, M
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 : S138 - S138